Open AccessNucleoside analog inhibits micro RNA ‐214 through targeting heat‐shock factor 1 in human epithelial ovarian cancer
Author(s) -
Chen YiFei,
Dong Zhangli,
Xia Yi,
Tang Jingjie,
Peng Ling,
Wang Shuying,
Lai Dongmei
Publication year - 2013
Publication title -
cancer science
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.035
H-Index - 141
eISSN - 1349-7006
pISSN - 1347-9032
DOI - 10.1111/cas.12277
Subject(s) - hsf1 , cancer research , ovarian cancer , microrna , biology , cancer , biogenesis , in vivo , heat shock protein , gene , hsp70 , biochemistry , genetics
The important functions of heat shock factor 1 (HSF1) in certain malignant cancers have granted it to be an appealing target for developing novel strategy for cancer therapy. Here, we report that higher HSF1 expression is associated with more aggressive malignization in epithelial ovarian tumors, indicating that targeting HSF1 is also a promising strategy against ovarian cancer. We found that a nucleoside analog (Ly101‐4B) elicits efficient inhibition on HSF1 expression and potent anticancer activity on epithelial ovarian cancer both in vitro and in vivo . Moreover, by targeting HSF1, Ly101‐4B inhibits the biogenesis of microRNA‐214, which has been revealed to be overexpressed and to promote cell survival in human ovarian epithelial tumors. These findings demonstrate that Ly101‐4B is a promising candidate for ovarian cancer therapy, and expand our understanding of HSF1, by revealing that it can regulate microRNA biogenesis in addition to its canonical function of regulating protein‐coding RNAs.